Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006; 355:51-65. https://doi.org/10.1056/NEJMra052166
Berwick M, Erdei E, Hay J. Melanoma epidemiology and public health. Dermatol Clin. 2009; 27:205-214, viii. https://doi.org/10.1016/j.det.2008.12.002
Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014; 383:816-27. https://doi.org/10.1016/ S0140-6736(13)60802-8
Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007; 445:851-7. https://doi.org/10.1038/nature05661
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949-54. https://doi. org/10.1038/nature00766
Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004; 5:875-85. https://doi.org/10.1038/nrm1498
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363:809-19. https://doi.org/10.1056/NEJMoa1002011
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364:2507-16. https://doi.org/10.1056/ NEJMoa1103782
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014; 4:80-93. https://doi. org/10.1158/2159-8290.CD-13-0642
Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Eur J Cancer. 2016; 55:98-110. https://doi.org/10.1016/j. ejca.2015.12.002
Najem A, Krayem M, Perdrix A, Kerger J, Awada A, Journe F, Ghanem G. New Drug Combination Strategies in Melanoma: Current Status and Future Directions. Anticancer Res. 2017; 37:5941-53. https://doi. org/10.21873/anticanres.12041
Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013; 19:1401-9. https://doi. org/10.1038/nm.3392
Hall BM, Balan V, Gleiberman AS, Strom E, Krasnov P, Virtuoso LP, Rydkina E, Vujcic S, Balan K, Gitlin I, Leonova K, Polinsky A, Chernova OB, et al. Aging of mice is associated with p16(Ink4a)-and β-galactosidasepositive macrophage accumulation that can be induced in young mice by senescent cells. Aging (Albany NY). 2016; 8:1294-315. https://doi.org/10.18632/aging.100991
Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, Kleijer WJ, DiMaio D, Hwang ES. Senescenceassociated beta-galactosidase is lysosomal betagalactosidase. Aging Cell. 2006; 5:187-95. https://doi. org/10.1111/j.1474-9726.2006.00199.x
Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436:720-4. https://doi.org/10.1038/nature03890
Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008; 132:363-74. https://doi.org/10.1016/j. cell.2007.12.032
Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004; 6:313-9. https://doi. org/10.1016/j.ccr.2004.09.022
Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 2006; 66:999-1006. https://doi.org/10.1158/0008-5472. CAN-05-2720
Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R. B-RAF is a therapeutic target in melanoma. Oncogene. 2004; 23:6292-8. https:// doi.org/10.1038/sj.onc.1207785
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011; 29:1239-46. https://doi.org/10.1200/ JCO.2010.32.4327
Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, Dobrovic A, McArthur G. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011; 24:666-72. https://doi.org/10.1111/j.1755-148X.2011.00873.x
Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, Bourque C, Burke CJ, Turner L, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011; 471:513-7. https://doi.org/10.1038/nature09806
de Keizer PL, Packer LM, Szypowska AA, Riedl-Polderman PE, van den Broek NJ, de Bruin A, Dansen TB, Marais R, Brenkman AB, Burgering BM. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. Cancer Res. 2010; 70:8526-36. https://doi.org/10.1158/0008-5472. CAN-10-1563
Mannava S, Omilian AR, Wawrzyniak JA, Fink EE, Zhuang D, Miecznikowski JC, Marshall JR, Soengas MS, Sears RC, Morrison CD, Nikiforov MA. PP2A-B56a controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene. 2012; 31:1484-92. https://doi. org/10.1038/onc.2011.339
Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhövel S, Hufnagel AL, Houben R, Meierjohann S. Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol. 2013; 133:1601-9. https://doi.org/10.1038/jid.2013.6
Xie X, Koh JY, Price S, White E, Mehnert JM. Atg7 overcomes senescence and promotes growth of BRAFV600E-driven melanoma. Cancer Discov. 2015; 5:410-23. https://doi.org/10.1158/2159-8290.CD-14-1473
Li Z, Jiang K, Zhu X, Lin G, Song F, Zhao Y, Piao Y, Liu J, Cheng W, Bi X, Gong P, Song Z, Meng S. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016; 370:332-44. https://doi. org/10.1016/j.canlet.2015.11.015
Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014; 508:118-22. https://doi.org/10.1038/nature13121
Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov. 2018; 8:74-93 https://doi.org/10.1158/2159-8290.CD-17-0682
Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015; 27:240-56. https://doi. org/10.1016/j.ccell.2014.11.018
Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song JY, Niessen HWM, Rozeman EA, Geukes Foppen MH, Blank CU, Peeper DS. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017; 550:270-4. https://doi.org/10.1038/nature24037
Srivastava SK, Bhardwaj A, Arora S, Tyagi N, Singh AP, Carter JE, Scammell JG, Fodstad Ø, Singh S. Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis. Br J Cancer. 2015; 112:1772-81. https://doi.org/10.1038/bjc.2015.154
Liu G, Zhang F, Lee J, Dong Z. Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-beta 1. Cytokine. 2005; 31:241-9. https://doi.org/10.1016/j.cyto.2005.03.008
Ha L, Merlino G, Sviderskaya EV. Melanomagenesis: Overcoming the Barrier of Melanocyte Senescence. Cell Cycle. 2008; 7:1944-8
Schreck R, Rapp UR. Raf kinases: oncogenesis and drug discovery. Int J Cancer. 2006; 119:2261-71. https://doi. org/10.1002/ijc.22144
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367:1694-703. https://doi. org/10.1056/NEJMoa1210093
Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19:1225-31. https://doi.org/10.1158/1078-0432.CCR-12-1630
Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012; 18:5329-40. https://doi. org/10.1158/1078-0432.CCR-12-1632
Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, et al. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med. 2017; 214:1691-1710. https://doi.org/10.1084/ jem.20160855
Ganesh K, Massagué J. TGF-β Inhibition and Immunotherapy: Checkmate. Immunity. 2018; 48:626-8. https://doi.org/10.1016/j.immuni.2018.03.037
Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017; 28:1988-95. https://doi.org/10.1093/annonc/mdx190
Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009; 69:8317-25. https://doi. org/10.1158/0008-5472.CAN-09-1248
Whipple CA, Brinckerhoff CE. BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. Br J Cancer. 2014; 111:1625-33. https://doi.org/10.1038/bjc.2014.452
Hartman ML, Rozanski M, Osrodek M, Zalesna I, Czyz M. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells. Lab Invest. 2017; 97:217-27. https://doi.org/10.1038/labinvest.2016.140
Wilmott JS, Haydu LE, Menzies AM, Lum T, Hyman J, Thompson JF, Hersey P, Kefford RF, Scolyer RA, Long GV. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J Immunol. 2014; 192:2505-13. https:// doi.org/10.4049/jimmunol.1302616
Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal. 2014; 7:ra30. https://doi. org/10.1126/scisignal.2004815
Beauséjour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003; 22:4212-22. https://doi.org/10.1093/emboj/cdg417
Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005; 37:961-76. https://doi.org/10.1016/j. biocel.2004.10.013
Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011; 192:547-56. https://doi.org/10.1083/ jcb.201009094
Yoshida A, Lee EK, Diehl JA. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. Cancer Res. 2016; 76:2990-3002 https://doi.org/10.1158/0008-5472.CAN-15-2931
Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, et al. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell. 2016; 29:75-89. https://doi.org/10.1016/j. ccell.2015.11.011
Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012; 26:1055-69. https://doi.org/10.1101/ gad.187252.112
Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, et al. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell. 2015; 27:41-56. https://doi.org/10.1016/j. ccell.2014.11.014
Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 2014; 15:1139-53. https://doi. org/10.15252/embr.201439245
Bryant CJ, Keyse SM, Caunt CJ. BRAF inhibitor resistance: are holidays and cocktails the answer? Pigment Cell Melanoma Res. 2014; 27:693-5. https://doi.org/10.1111/ pcmr.12291
Deschênes-Simard X, Kottakis F, Meloche S, Ferbeyre G. ERKs in cancer: friends or foes? Cancer Res. 2014; 74:412-9. https://doi.org/10.1158/0008-5472.CAN-13-2381
Dooley AJ, Gupta A, Middleton MR. Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report. Target Oncol. 2016; 11:557-63. https://doi.org/10.1007/ s11523-015-0410-9
Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013; 31:e300-303. https://doi. org/10.1200/JCO.2012.45.9495
Krayem M, Journe F, Wiedig M, Morandini R, Sales F, Awada A, Ghanem G. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib. Eur J Cancer. 2014; 50:1310-20. https://doi.org/10.1016/j. ejca.2014.01.021
Najem A, Krayem M, Salès F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem GE. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. Eur J Cancer. 2017; 83:154-65. https://doi.org/10.1016/j. ejca.2017.06.033
Plovins A, Alvarez AM, Ibañez M, Molina M, Nombela C. Use of fluorescein-di-beta-D-galactopyranoside (FDG) and C12-FDG as substrates for beta-galactosidase detection by flow cytometry in animal, bacterial, and yeast cells. Appl Environ Microbiol. 1994; 60:4638-41
Gary RK, Kindell SM. Quantitative assay of senescenceassociated beta-galactosidase activity in mammalian cell extracts. Anal Biochem. 2005; 343:329-34. https://doi. org/10.1016/j.ab.2005.06.003
Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 2009; 4:1798-806. https://doi.org/10.1038/nprot.2009.191
